nach oben

European Journal of Nutrition

Erschienen in:

21.12.2023 | Original Contribution

Curcumin inhibits the invasion and migration of pancreatic cancer cells by upregulating TFPI-2 to regulate ERK- and JNK-mediated epithelial–mesenchymal transition

verfasst von: Lu-Lu Zhai, Wei-Bo Li, Long-Jiang Chen, Wei Wang, Tong-Fa Ju, Da-Long Yin

Erschienen in: European Journal of Nutrition | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pancreatic cancer (PC) is one of the most deadly human malignancies. Curcumin is a natural polyphenolic compound with wide-ranging pharmacological effects. Growing evidence suggests that curcumin has anticancer activity against PC, but the mechanism remains incompletely elucidated. This study aimed to investigate the effects and mechanisms of curcumin on the invasion and migration of PC cells.

Methods

Effect of curcumin on tissue factor pathway inhibitor (TFPI)-2 mRNA expression in PC cells was initially identified using qRT-PCR. Cytotoxicity of curcumin was assessed with MTT assays and IC50 was calculated. Involvement of ERK and JNK pathways, as well as protein expression of TFPI-2 and epithelial–mesenchymal transition (EMT)-related markers, were detected using immunoblotting. Invasion and migration of PC cells were examined using Transwell assays. TFPI-2 expression was manipulated by transfection with siRNA and shRNA. Rescue assays were used to validate the effect of curcumin on cell invasion and migration via TFPI-2.

Results

Curcumin increased the expression of TFPI-2 mRNA and protein in PC cells and attenuated cell invasion and migration. Curcumin also inhibited ERK and JNK pathways and EMT in PC cells. Knockdown of TFPI-2 partially reversed the inhibition of ERK and JNK pathways and EMT by curcumin. Mechanistically, curcumin upregulated TFPI-2, thereby inhibiting the ERK and JNK pathways, leading to the inhibition of EMT in PC cells.

Conclusion

Collectively, curcumin inhibits ERK- and JNK-mediated EMT through upregulating TFPI-2, which in turn suppresses the migration and invasion of PC cells. These findings provide new insights into the antitumor mechanism of curcumin.

Nur mit Berechtigung zugänglich

Wu W, He X, Yang L, Wang Q, Bian X, Ye J, Li Y, Li L (2018) Rising trends in pancreatic cancer incidence and mortality in 2000–2014. Clin Epidemiol 10:789–797. https://doi.org/10.2147/CLEP.S160018CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708CrossRefPubMed

Kempaiah P, Chand HS, Kisiel W (2007) Identification of a human TFPI-2 splice variant that is upregulated in human tumor tissues. Mol Cancer 6:20. https://doi.org/10.1186/1476-4598-6-20CrossRefPubMedPubMedCentral

Wojtukiewicz MZ, Sierko E, Zimnoch L, Kozlowski L, Kisiel W (2003) Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 90(1):140–146PubMed

Zhai LL, Wu Y, Huang DW, Tang ZG (2015) Increased matrix metalloproteinase-2 expression and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma. Am J Transl Res 7(11):2412–2422PubMedPubMedCentral

Zhai LL, Cai CY, Wu Y, Tang ZG (2015) Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma. Int J Clin Exp Pathol 8(1):682–691PubMedPubMedCentral

Zhai LL, Wu Y, Cai CY, Tang ZG (2015) Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma. Onco Targets Ther 8:2827–2834. https://doi.org/10.2147/OTT.S90599CrossRefPubMedPubMedCentral

Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, Goggins M (2005) Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24(5):850–858. https://doi.org/10.1038/sj.onc.1208050CrossRefPubMed

Tang Z, Geng G, Huang Q, Xu G, Hu H, Chen J, Li J (2011) Expression of tissue factor pathway inhibitor 2 in human pancreatic carcinoma and its effect on tumor growth, invasion, and migration in vitro and in vivo. J Surg Res 167(1):62–69. https://doi.org/10.1016/j.jss.2009.06.015CrossRefPubMed

10.

Wang W, He Y, Zhai LL, Chen LJ, Yao LC, Wu L, Tang ZG, Ning JZ (2022) m6A RNA demethylase FTO promotes the growth, migration and invasion of pancreatic cancer cells through inhibiting TFPI-2. Epigenetics 17(12):1738–1752. https://doi.org/10.1080/15592294.2022.2061117CrossRefPubMedPubMedCentral

11.

Lavergne M, Jourdan ML, Blechet C, Guyetant S, Pape AL, Heuze-Vourc’h N, Courty Y, Lerondel S, Sobilo J, Iochmann S, Reverdiau P (2013) Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer. FEBS Open Bio 3:291–301. https://doi.org/10.1016/j.fob.2013.06.004CrossRefPubMedPubMedCentral

12.

Wang G, Zeng Y, Chen S, Li D, Li W, Zhou Y, Singer RH, Gu W (2017) Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells. Sci Rep 7(1):13575. https://doi.org/10.1038/s41598-017-14148-8ADSCrossRefPubMedPubMedCentral

13.

Wang G, Huang W, Li W, Chen S, Chen W, Zhou Y, Peng P, Gu W (2018) TFPI-2 suppresses breast cancer cell proliferation and invasion through regulation of ERK signaling and interaction with actinin-4 and myosin-9. Sci Rep 8(1):14402. https://doi.org/10.1038/s41598-018-32698-3ADSCrossRefPubMedPubMedCentral

14.

Do HTT, Cho J (2020) Involvement of the ERK/HIF-1α/EMT pathway in XCL1-induced migration of MDA-MB-231 and SK-BR-3 breast cancer cells. Int J Mol Sci 22(1):89. https://doi.org/10.3390/ijms22010089CrossRefPubMedPubMedCentral

15.

Lee S, Rauch J, Kolch W (2020) Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci 21(3):1102. https://doi.org/10.3390/ijms21031102CrossRefPubMedPubMedCentral

16.

Xue M, Sun H, Xu R, Wang Y, Guo J, Li X, Cheng Y, Xu C, Tang C, Sun B, Chen L (2020) GADD45B promotes glucose-induced renal tubular epithelial–mesenchymal transition and apoptosis via the p38 MAPK and JNK signaling pathways. Front Physiol 11:1074. https://doi.org/10.3389/fphys.2020.01074CrossRefPubMedPubMedCentral

17.

Wu Q, Wu W, Jacevic V, Franca TCC, Wang X, Kuca K (2020) Selective inhibitors for JNK signalling: a potential targeted therapy in cancer. J Enzyme Inhibit Med Chem 35(1):574–583. https://doi.org/10.1080/14756366.2020.1720013CrossRef

18.

Bimonte S, Barbieri A, Leongito M, Piccirillo M, Giudice A, Pivonello C, de Angelis C, Granata V, Palaia R, Izzo F (2016) Curcumin anticancer studies in pancreatic cancer. Nutrients 8(7):433. https://doi.org/10.3390/nu8070433CrossRefPubMedPubMedCentral

19.

Nagaraju GP, Benton L, Bethi SR, Shoji M, El-Rayes BF (2019) Curcumin analogs: their roles in pancreatic cancer growth and metastasis. Int J Cancer 145(1):10–19. https://doi.org/10.1002/ijc.31867CrossRefPubMed

20.

Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R (2004) Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101(10):2351–2362. https://doi.org/10.1002/cncr.20605CrossRefPubMed

21.

Bimonte S, Barbieri A, Palma G, Luciano A, Rea D, Arra C (2013) Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer. Biomed Res Int 2013:810423. https://doi.org/10.1155/2013/810423CrossRefPubMedPubMedCentral

22.

Jutooru I, Chadalapaka G, Lei P, Safe S (2010) Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 285(33):25332–25344. https://doi.org/10.1074/jbc.M109.095240CrossRefPubMedPubMedCentral

23.

Youns M, Fathy GM (2013) Upregulation of extrinsic apoptotic pathway in curcumin-mediated antiproliferative effect on human pancreatic carcinogenesis. J Cell Biochem 114(12):2654–2665. https://doi.org/10.1002/jcb.24612CrossRefPubMed

24.

Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67(8):3853–3861. https://doi.org/10.1158/0008-5472.CAN-06-4257CrossRefPubMed

25.

Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, Chenna V, Karikari C, Sharma R, Goggins MG, Rudek MA, Ravi R, Maitra A, Maitra A (2010) Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther 9(8):2255–2264. https://doi.org/10.1158/1535-7163.MCT-10-0172CrossRefPubMedPubMedCentral

26.

Li W, Sun L, Lei J, Wu Z, Ma Q, Wang Z (2020) Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor-stromal crosstalk under hypoxic conditions via the IL-6/ERK/NF-κB axis. Oncol Rep 44(1):382–392. https://doi.org/10.3892/or.2020.7600CrossRefPubMed

27.

Li W, Jiang Z, Xiao X, Wang Z, Wu Z, Ma Q, Cao L (2018) Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells. Int J Oncol 52(5):1593–1602. https://doi.org/10.3892/ijo.2018.4295CrossRefPubMed

28.

Zhao Z, Li C, Xi H, Gao Y, Xu D (2015) Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway. Mol Med Rep 12(4):5415–5422. https://doi.org/10.3892/mmr.2015.4060CrossRefPubMed

29.

Sun XD, Liu XE, Huang DS (2013) Curcumin reverses the epithelial–mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway. Oncol Rep 29(6):2401–2407. https://doi.org/10.3892/or.2013.2385CrossRefPubMed

30.

Cao L, Xiao X, Lei J, Duan W, Ma Q, Li W (2016) Curcumin inhibits hypoxia-induced epithelial–mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway. Oncol Rep 35(6):3728–3734. https://doi.org/10.3892/or.2016.4709CrossRefPubMed

31.

Basha R, Connelly SF, Sankpal UT, Nagaraju GP, Patel H, Vishwanatha JK, Shelake S, Tabor-Simecka L, Shoji M, Simecka JW, El-Rayes B (2016) Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution. J Nutr Biochem 31:77–87. https://doi.org/10.1016/j.jnutbio.2016.01.003CrossRefPubMedPubMedCentral

32.

Glienke W, Maute L, Wicht J, Bergmann L (2010) Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest 28(2):166–71. https://doi.org/10.3109/07357900903287006CrossRefPubMed

33.

Sahu RP, Batra S, Srivastava SK (2009) Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer 100(9):1425–1433. https://doi.org/10.1038/sj.bjc.6605039CrossRefPubMedPubMedCentral

34.

Díaz Osterman CJ, Gonda A, Stiff T, Sigaran U, Valenzuela MM, Ferguson Bennit HR, Moyron RB, Khan S, Wall NR (2016) Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis. Pancreas 45(1):101–109. https://doi.org/10.1097/MPA.0000000000000411CrossRefPubMed

35.

Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi Y, Wu X, Cheng L, Ma C, Xia J, Wang Z (2014) Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol Lett 231(1):82–91. https://doi.org/10.1016/j.toxlet.2014.09.014CrossRefPubMed

36.

Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, Philip PA, Li Y (2013) Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res 3(5):465–477PubMedPubMedCentral

37.

Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH (2012) Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72(1):335–345. https://doi.org/10.1158/0008-5472.CAN-11-2182CrossRefPubMed

38.

Giordano A, Tommonaro G (2019) Curcumin and Cancer. Nutrients 11(10):2376. https://doi.org/10.3390/nu11102376CrossRefPubMedPubMedCentral

39.

Hu C, Li M, Guo T, Wang S, Huang W, Yang K, Liao Z, Wang J, Zhang F, Wang H (2019) Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT. Phytomedicine 58:152740. https://doi.org/10.1016/j.phymed.2018.11.001CrossRefPubMed

40.

Li M, Guo T, Lin J, Huang X, Ke Q, Wu Y, Fang C, Hu C (2022) Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway. J Ethnopharmacol 283:114689. https://doi.org/10.1016/j.jep.2021.114689CrossRefPubMed

41.

Wang L, Wang C, Tao Z, Zhao L, Zhu Z, Wu W, He Y, Chen H, Zheng B, Huang X, Yu Y, Yang L, Liang G, Cui R, Chen T (2019) Curcumin derivative WZ35 inhibits tumor cell growth via ROS-YAP-JNK signaling pathway in breast cancer. J Exp Clin Cancer Res 38(1):460. https://doi.org/10.1186/s13046-019-1424-4CrossRefPubMedPubMedCentral

42.

Chen QY, Zheng Y, Jiao DM, Chen FY, Hu HZ, Wu YQ, Song J, Yan J, Wu LJ, Lv GY (2014) Curcumin inhibits lung cancer cell migration and invasion through Rac1-dependent signaling pathway. J Nutr Biochem 25(2):177–185. https://doi.org/10.1016/j.jnutbio.2013.10.004CrossRefPubMed

43.

Lai YH, He RY, Chou JL, Chan MW, Li YF, Tai CK (2014) Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma. J Transl Med 12:237. https://doi.org/10.1186/s12967-014-0237-7CrossRefPubMedPubMedCentral

44.

Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP, Ng IO (2007) Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45(5):1129–1138. https://doi.org/10.1002/hep.21578CrossRefPubMed

45.

Hepworth EMW, Hinton SD (2021) Pseudophosphatases as regulators of MAPK signaling. Int J Mol Sci 22(22):12595. https://doi.org/10.3390/ijms222212595CrossRefPubMedPubMedCentral

46.

Asl ER, Amini M, Najafi S, Mansoori B, Mokhtarzadeh A, Mohammadi A, Lotfinejad P, Bagheri M, Shirjang S, Lotfi Z, Rasmi Y, Baradaran B (2021) Interplay between MAPK/ERK signaling pathway and microRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci 278:119499. https://doi.org/10.1016/j.lfs.2021.119499CrossRefPubMed

47.

Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, Yang R, Edwards AC, Walsh KH, Sulahian R, McFarland JM, Kapner KS, Gilbert TSK, Stalnecker CA, Javaid S, Barkovskaya A, Grover KR, Hibshman PS, Blake DR, Schaefer A, Nowak KM, Klomp JE, Hayes TK, Kassner M, Tang N, Tanaseichuk O, Chen K, Zhou Y, Kalkat M, Herring LE, Graves LM, Penn LZ, Yin HH, Aguirre AJ, Hahn WC, Cox AD, Der CJ (2021) Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep 35(13):109291. https://doi.org/10.1016/j.celrep.2021.109291CrossRefPubMedPubMedCentral

48.

Xu JC, Chen TY, Liao LT, Chen T, Li QL, Xu JX, Hu JW, Zhou PH, Zhang YQ (2021) NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway. Int J Biol Sci 17(1):259–270. https://doi.org/10.7150/ijbs.53795CrossRefPubMedPubMedCentral

49.

Jiang T, Wu H, Lin M, Yin J, Tan L, Ruan Y, Feng M (2021) B4GALNT1 promotes progression and metastasis in lung adenocarcinoma through JNK/c-Jun/Slug pathway. Carcinogenesis 42(4):621–630. https://doi.org/10.1093/carcin/bgaa141CrossRefPubMed

50.

Liu M, Zhang Y, Yang J, Cui X, Zhou Z, Zhan H, Ding K, Tian X, Yang Z, Fung KA, Edil BH, Postier RG, Bronze MS, Fernandez-Zapico ME, Stemmler MP, Brabletz T, Li YP, Houchen CW, Li M (2020) ZIP4 increases expression of transcription factor ZEB1 to promote integrin α3β1 signaling and inhibit expression of the gemcitabine transporter ENT1 in pancreatic cancer cells. Gastroenterology 158(3):679-692.e1. https://doi.org/10.1053/j.gastro.2019.10.038CrossRefPubMed

51.

Xing M, Yang Y, Huang J, Fang Y, Jin Y, Li L, Chen X, Zhu X, Ma C (2022) TFPI inhibits breast cancer progression by suppressing ERK/p38 MAPK signaling pathway. Genes Genomics 44(7):801–812. https://doi.org/10.1007/s13258-022-01258-5CrossRefPubMed

52.

Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N (2010) Overexpression of both TFPIα and TFPIβ induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Mol Carcinogen 49(11):951–963. https://doi.org/10.1002/mc.20679CrossRef

53.

Subbiah V, Baik C, Kirkwood JM (2020) Clinical development of BRAF plus MEK inhibitor combinations. Trends Cancer 6(9):797–810. https://doi.org/10.1016/j.trecan.2020.05.009CrossRefPubMed

54.

Del Bufalo D, Di Martile M, Valentini E, Manni I, Masi I, D’Amore A, Filippini A, Nicoletti C, Zaccarini M, Cota C, Castro MV, Quezada MJ, Rosanò L, Lopez-Bergami P, D’Aguanno S (2022) Bcl-2-like protein-10 increases aggressive features of melanoma cells. Explor Target Antitumor Ther 3(1):11–26. https://doi.org/10.37349/etat.2022.00068CrossRefPubMedPubMedCentral

55.

Tan X, Chen D, Guo S, Wang Y, Zou Y, Wu Z, Zhou F, Qin Z, Liu Z, Cao Y, Lin C, Yuan G, Yao K (2021) Molecular stratification by BCL2A1 and AIM2 provides additional prognostic value in penile squamous cell carcinoma. Theranostics 11(3):1364–1376. https://doi.org/10.7150/thno.51725CrossRefPubMedPubMedCentral

56.

Józefiak A, Larska M, Pomorska-Mól M, Ruszkowski JJ (2021) The IGF-1 signaling pathway in viral infections. Viruses 13(8):1488. https://doi.org/10.3390/v13081488CrossRefPubMedPubMedCentral

57.

Xu Z, Maiti D, Kisiel W, Duh EJ (2006) Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler Thromb Vasc Biol 26(12):2819–2825. https://doi.org/10.1161/01.ATV.0000248731.55781.87CrossRefPubMed

58.

Huang L, Chen S, Fan H, Ji D, Chen C, Sheng W (2021) GINS2 promotes EMT in pancreatic cancer via specifically stimulating ERK/MAPK signaling. Cancer Gene Ther 28(7–8):839–849. https://doi.org/10.1038/s41417-020-0206-7CrossRefPubMed

59.

Zheng J, Shi Z, Yang P, Zhao Y, Tang W, Ye S, Xuan Z, Chen C, Shao C, Wu Q, Sun H (2022) ERK-Smurf1-RhoA signaling is critical for TGFβ-drived EMT and tumor metastasis. Life Sci Alliance 5(10):e202101330. https://doi.org/10.26508/lsa.202101330CrossRefPubMedPubMedCentral

60.

Sun XY, Li HZ, Xie DF, Gao SS, Huang X, Guan H, Bai CJ, Zhou PK (2022) LPAR5 confers radio resistance to cancer cells associated with EMT activation via the ERK/Snail pathway. J Transl Med 20(1):456. https://doi.org/10.1186/s12967-022-03673-4CrossRefPubMedPubMedCentral

61.

Tam SY, Wu VWC, Law HKW (2020) JNK pathway mediates low oxygen level induced epithelial–mesenchymal transition and stemness maintenance in colorectal cancer cells. Cancers (Basel) 12(1):224. https://doi.org/10.3390/cancers12010224CrossRefPubMed

62.

Pang B, Wu N, Guan R, Pang L, Li X, Li S, Tang L, Guo Y, Chen J, Sun D, Sun H, Dai J, Bai J, Ji G, Liu P, Liu A, Wang Q, Xiao S, Fu S, Jin Y (2017) Overexpression of RCC2 enhances cell motility and promotes tumor metastasis in lung adenocarcinoma by inducing epithelial–mesenchymal transition. Clin Cancer Res 23(18):5598–5610. https://doi.org/10.1158/1078-0432.CCR-16-2909CrossRefPubMed

63.

Wang JF, Zhao K, Chen YY, Qiu Y, Zhu JH, Li BP, Wang Z, Chen JQ (2021) NKCC1 promotes proliferation, invasion and migration in human gastric cancer cells via activation of the MAPK-JNK/EMT signaling pathway. J Cancer 12(1):253–263. https://doi.org/10.7150/jca.49709CrossRefPubMedPubMedCentral

Titel: Curcumin inhibits the invasion and migration of pancreatic cancer cells by upregulating TFPI-2 to regulate ERK- and JNK-mediated epithelial–mesenchymal transition
verfasst von: Lu-Lu Zhai
Wei-Bo Li
Long-Jiang Chen
Wei Wang
Tong-Fa Ju
Da-Long Yin
Publikationsdatum: 21.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 2/2024
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-023-03296-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Auf Antibiotika verzichten? Was bei unkomplizierter Zystitis hilft

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Inverse association between Paleolithic Diet Fraction and mortality and incidence of cardiometabolic disease in the prospective Malmö Diet and Cancer Study

Whole grain intake, diet quality and risk factors of chronic diseases: results from a population-based study in Finnish adults

Association between healthy dietary patterns and markers of oxidative stress in the Sister Study

Ultra-processed foods, adiposity and risk of head and neck cancer and oesophageal adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition study: a mediation analysis

Greater adherence to the Healthy Nordic Food Index is associated with lower all-cause mortality in a population-based sample from northern Germany